All the news Showing 8 of 248 articles from: Interferon-free regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources 94% response rate to HCV treatment without ribavirin or interferon in harder-to-treat Keith Alcorn / 13 November 2012 Twelve weeks of treatment with a three-drug combination of new directly acting antivirals that contained neither pegylated interferon nor ribavirin led to a sustained virologic response 12 weeks after completion of treatment (SVR12) ... Abbott interferon-free combination 'promising' in harder-to-treat patients with hepatitis C Keith Alcorn / 12 November 2012 Over 79% of previously untreated and null responder patients with genotype 1a hepatitis infection achieved a sustained virologic response twelve weeks after completing treatment (SVR12) with an interferon-free combination of two or three ... High rate of response to BMS HCV drugs in harder-to-treat patients – but interferon-free prospects differ by sub-genotype Keith Alcorn / 12 November 2012 Although an interferon-free combination of antiviral drugs developed by Bristol-Myers Squibb to treat hepatitis C was highly effective in curing the infection in previous null responders to treatment with HCV genotype 1b infection, ... BI 201335 & BI 207127 and ribavirin shows good efficacy, including hepatitis C patients with cirrhosis Liz Highleyman / 15 May 2012 An interferon-free regimen of the hepatitis C virus (HCV) protease inhibitor BI 201335, the non-nucleoside polymerase inhibitor BI 207127, and ribavirin produced sustained virological response in 68% of previously untreated genotype 1 hepatitis C ... GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks Liz Highleyman / 30 April 2012 Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the ... Abbott interferon-free HCV combinations show early promise in untreated patients Caspar Thomson / 23 April 2012 Two interferon-free antiviral regimens being developed by Abbott showed high hepatitis C cure rates in small studies of treatment-naïve patients presented last week at the International Liver Congress in Barcelona. Abbott is pursuing the ... GS-7977 plus ribavirin rapidly suppresses HCV but most patients relapse Liz Highleyman / 07 March 2012 An interferon-free combination of the experimental polymerase inhibitor GS-7977 plus ribavirin potently and rapidly reduced hepatitis C virus (HCV) levels, but almost all patients experienced viral rebound after they stopped treatment, researchers reported ... New hepatitis C drugs pose many questions Keith Alcorn / 08 April 2011 Even before new hepatitis C drugs come to market later this year, the vast array of hepatitis C antivirals currently in clinical trials is opening up new horizons for treatment of hepatitis ... ← Prev1...2122232425Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive